All In Biotech

BLA 761166 · Pharmaessentia Corp

Besremi

Ropeginterferon Alfa-2b-Njft · Subcutaneous · Interferon alfa-2b

NovelOrphan

CDER novel approval, Nov 12, 2021: To treat polycythemia vera, a blood disease that causes the overproduction of red blood cells

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 12, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

31

11 Phase 3, 9 recruiting

FAERS reports

1,859

429 serious, 31 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS DISORDERS Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping therapy [see Warnings and Precautions ( 5.1 , 5,2 , 5.3 , 5.4 ) and Adverse Reactions ( 6.1 )] . WARNING: RISK OF SERIOUS DISORDERS See full prescribing information for complete boxed warning. Risk of Serious Disorders: Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or...

What it is approved for

From the label in effect Aug 25, 2026.

BESREMi is an interferon alfa-2b indicated for: • The treatment of adults with essential thrombocythemia. ( 1.1 ) • The treatment of adults with polycythemia vera. ( 1.2 ) 1.1 Essential Thrombocythemia BESREMi is indicated for the treatment of adults with essential thrombocythemia. 1.2 Polycythemia Vera BESREMi is indicated for the treatment of adults with polycythemia vera.

Mechanism: Interferon alfa belongs to the class of type I interferons, which exhibit their cellular effects in polycythemia vera and essential thrombocythemia in the bone marrow by binding to a transmembrane receptor termed interferon alfa receptor (IFNAR). Binding to IFNAR initiates a downstream signaling cascade through the activation of kinases, in particular Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2) and activator of transcription (STAT) proteins. Nuclear translocation of STAT proteins controls distinct gene-expression programs and exhibits various cellular effects. The actions involved in...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BESREMI · ROPEGINTERFERON ALFA-2B-NJFT 500 MCG/ML · INJECTABLE, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ropeginterferon Alfa-2b" as an intervention, any sponsor and status, largest first.

All 31 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue355
  • off label use304
  • pruritus177
  • headache157
  • product dose omission issue118
  • influenza like illness111
  • nausea110
  • inappropriate schedule of product administration107
  • diarrhoea104
  • pain104
  • arthralgia101
  • haematocrit increased93

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20173
20201
20211
2022382
2023774
2024217
2025189
2026292

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Besremi (Ropeginterferon Alfa-2b-Njft)

2024 spending

$81.2M

Beneficiaries

704

5,334 claims

Per beneficiary

$115,338

$8,230.93 per unit

View as table
YearSpending
2020$0
2021$0
2022$20,049,428
2023$39,923,392
2024$81,198,106

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Pharmaessentia Corp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.